NextPlat (NXPL) Cash from Financing Activities (2010 - 2026)
NextPlat's (NXPL) quarterly Cash from Financing Activities came in at -$147000.0 in Q2 2026, down 15.75% year-over-year from -$174476.6 in Q2 2025, and down 4.26% quarter-over-quarter from -$141000.0 in Q1 2026.
Powered by 
Analysis
NextPlat (NXPL) Cash from Financing Activities (2010 - 2026) Analysis & Trends
NextPlat (NXPL) has reported Cash from Financing Activities for 15 consecutive years, with -$147000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash from Financing Activities fell 15.75% year-over-year to -$147000.0 in Q2 2026; TTM through Jun 2026 was -$252000.0, a 62.58% decrease from a year earlier, with the FY2025 full-year figure at -$225000.0, down 412.5% from the prior year.
- Cash from Financing Activities was -$147000.0 for Q2 2026 at NextPlat, down from -$141000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $7.5 million in Q4 2022 and troughed at -$470000.0 in Q4 2023.
- A 5-year average of $1.0 million and a median of -$8999.5 in 2022 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities soared 9031.57% in 2023 and tumbled 13300.0% in 2025, its largest moves.
- Over 5 years, Cash from Financing Activities stood at $7.5 million in 2022, then plunged by 106.29% to -$470000.0 in 2023, then surged by 104.68% to $22000.0 in 2024, then surged by 504.55% to $133000.0 in 2025, then plunged by 210.53% to -$147000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$147000.0 (Q2 2026), -$141000.0 (Q1 2026), and $133000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | -1.00 Mn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | -1.24 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | -75.18 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 79.36 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | -49.00 Mn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | -4.65 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | 143.38 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | -43.54 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | - |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | -147,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -147,000.00 |
| Mar 31, 2026 | -141,000.00 |
| Dec 31, 2025 | 133,000.00 |
| Sep 30, 2025 | -97,000.00 |
| Jun 30, 2025 | -127,000.00 |
| Mar 31, 2025 | -134,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Sep 30, 2024 | 84,000.00 |
| Jun 30, 2024 | -33,000.00 |
| Mar 31, 2024 | -1,000.00 |
| Dec 31, 2023 | -470,000.00 |
| Sep 30, 2023 | 177,000.00 |
| Jun 30, 2023 | 6.17 Mn |
| Mar 31, 2023 | -13,000.00 |
| Dec 31, 2022 | 7.48 Mn |
| Sep 30, 2022 | -4,999.00 |
| Jun 30, 2022 | -69,036.00 |
| Mar 31, 2022 | 5.61 Mn |
| Dec 31, 2021 | 1.35 Mn |
| Sep 30, 2021 | 4.47 Mn |